Dr. Reddy’s Laboratories informs about disclosure

29 Dec 2022 Evaluate

Dr. Reddy’s Laboratories has informed that, on November 22, 2022, the company and Dr. Reddy’s Laboratories, Inc. (a wholly owned subsidiary of the Company) had been named as defendants, along with Celgene, Bristol Myers Squibb, and several other generic pharmaceutical companies, in a complaint that asserts claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States. On December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr. Reddy’s Laboratories and Dr. Reddy’s Laboratories, Inc., respectively, from the case. All claims against the Company in the litigation have now been dismissed.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1254.70 -16.35 (-1.29%)
01-Jan-2026 10:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.55
Dr. Reddys Lab 1254.70
Cipla 1503.65
Zydus Lifesciences 908.85
Lupin 2084.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×